Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
about
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cellsCorepressor protein CDYL functions as a molecular bridge between polycomb repressor complex 2 and repressive chromatin mark trimethylated histone lysine 27Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastomaDACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modificationsmiR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesisLong non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasisPharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancerA histone demethylase is necessary for regeneration in zebrafishHistone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RASTargeting histone methyltransferases and demethylases in clinical trials for cancer therapyTargeting EZH2 in cancerGlobal histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment?The complexity of epigenetic diseasesPolycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic ImplicationsEpigenomics of leukemia: from mechanisms to therapeutic applicationsLinking epithelial-to-mesenchymal-transition and epigenetic modificationsCombating the epigenome: epigenetic drugs against non-Hodgkin's lymphomaRecent progress toward epigenetic therapies: the example of mixed lineage leukemiaEpigenetics in breast cancer: what's new?Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and preventionEpigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectivesAltered histone modifications in gliomasPPARĪ² interprets a chromatin signature of pluripotency to promote embryonic differentiation at gastrulationStructures of histone methyltransferase SET7/9 in complexes with adenosylmethionine derivativesPrognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysisPD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsEZH2 in Bladder Cancer, a Promising Therapeutic TargetEpigenome-based personalized medicine in human cancerDiverse involvement of EZH2 in cancer epigeneticsEpigenetic regulation of endothelial-cell-mediated vascular repairMicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD)Nucleoside drugs induce cellular differentiation by caspase-dependent degradation of stem cell factorsPharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studiesDeazaneplanocin a is a promising drug to kill multiple myeloma cells in their nicheFunctional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elementsEpigenetics in cancerCan a metastatic gene expression profile outperform tumor size as a predictor of occult lymph node metastasis in oral cancer patients?Gene set-based module discovery in the breast cancer transcriptome.CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells
P2860
Q24293124-F42D3F6C-5C30-43DD-B37E-98218361713DQ24293669-F5B73080-9406-4BEF-AA15-9AA5D2FEF95CQ24300058-6F622890-1441-4C5C-8448-6DA536137297Q24319915-5001E88D-A8DC-4FDF-916A-D13A4E9DF10AQ24604354-48D7975C-6F4B-4AAA-A562-9B2473C4A736Q24607308-F063B854-0457-43B1-82EB-257C11B79128Q24632276-301EB914-F2AC-4DB7-BF87-F18553D24096Q24648837-4CD54289-7205-4867-8E5D-02AD665B2297Q24657459-94BA7AC9-6452-43E8-AD1E-90D1607F0B78Q26746038-D2098758-0335-4FD2-A421-FFFCB6FE7A13Q26769027-A5BEBDFA-11A7-47E1-B4B4-AC0238555A5EQ26775413-AAB3175D-26F1-4DAB-8352-072FB15B173FQ26784416-A7110EA1-C1B1-472F-A2F7-2D2BC84C6171Q26801380-5212BBCF-3E8A-4F8B-B1E3-6615FA49466BQ26823403-4E8AD9A5-7FFD-4D75-9ED3-280ACFE3532EQ26824575-287A6A3F-8212-4603-9642-55AF3348A1A8Q26851166-CE91C203-242A-4345-B341-3811998589BBQ26863577-0F98AF49-D18E-4818-AFE2-6FEB006D2004Q26991779-A047709F-08CA-47D1-A1BC-FB5EA93366E3Q26994739-1DEF7C84-5840-4CF6-938A-545ACD460EBCQ26999187-4C1C7281-8FED-4238-803B-4D6A608CB246Q27027924-F552D36D-D66D-4027-9C2A-042589B422CFQ27340116-8BE9B31E-5F37-432E-960C-1A6E77D95B2EQ27684252-D5E4D642-F958-46E5-A7A2-04951E9AE123Q27853296-B79969C5-0E1E-48B5-93C8-2387E7E05C60Q28075712-41BE0B4E-02EB-4D91-9AF0-EEC3936E3F79Q28082054-627F3F46-3708-4168-8454-0EC8E6703933Q28083951-2088F8CE-BD5D-45F8-82A0-9F69F3589AE0Q28084911-D73F385E-AB7E-4863-8522-2F71F40D5158Q28085420-55036495-40DE-4B86-A17F-CD99C28529CFQ28280193-326C3ACB-91A6-4F20-B1D9-FDAE95A6950EQ28473971-78D53BC6-906A-4760-87AD-F4CC2AB140BBQ28535154-845FE0C5-9C0C-41CD-8EA2-6FA27C0F1A3CQ28543228-CAC0738F-0CDE-45BF-B519-932D01365FA9Q28546856-BF46AE6E-1A0D-43FA-8831-6AE17B2ECF0BQ28828237-F048884D-D855-4B14-89B4-A832192348BDQ29617139-DF22AB8B-B192-4970-8268-9AD071D45AB7Q30499736-058BC236-C867-45EB-B4A9-3E06132AF1F1Q33412610-0C98DEB2-2186-4718-B1D9-6913F88D58E7Q33425892-B3BEAE85-5541-47E9-90A2-DB40B65E0DEA
P2860
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
description
2007 nĆ® lÅ«n-bĆ»n
@nan
2007 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« Ō±ÕŗÖÕ«Õ¬Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2007 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ”ÕŗÖÕ«Õ¬Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2007幓ć®č«ę
@ja
2007幓č«ę
@yue
2007幓č«ę
@zh-hant
2007幓č«ę
@zh-hk
2007幓č«ę
@zh-mo
2007幓č«ę
@zh-tw
2007幓č®ŗę
@wuu
name
Pharmacologic disruption of Po ...... uces apoptosis in cancer cells
@ast
Pharmacologic disruption of Po ...... uces apoptosis in cancer cells
@en
Pharmacologic disruption of Po ...... uces apoptosis in cancer cells
@nl
type
label
Pharmacologic disruption of Po ...... uces apoptosis in cancer cells
@ast
Pharmacologic disruption of Po ...... uces apoptosis in cancer cells
@en
Pharmacologic disruption of Po ...... uces apoptosis in cancer cells
@nl
prefLabel
Pharmacologic disruption of Po ...... uces apoptosis in cancer cells
@ast
Pharmacologic disruption of Po ...... uces apoptosis in cancer cells
@en
Pharmacologic disruption of Po ...... uces apoptosis in cancer cells
@nl
P2093
P2860
P356
P1433
P1476
Pharmacologic disruption of Po ...... uces apoptosis in cancer cells
@en
P2093
Edison T Liu
Patrick Boon Ooi Tan
Puay Leng Lee
R K Murthy Karuturi
Xiaojing Yang
P2860
P304
P356
10.1101/GAD.1524107
P577
2007-04-16T00:00:00Z